Our Network

Strong Network of Physicians & Clinical Sites

We are proud to collaborate with many of the leading cancer centers and physicians in the country. Our extensive clinical research network enables us to leverage several key benefits of investigator-initiated trials (IITs) to complement our company-sponsored trials. IITs enable us to be as close to addressing the true unmet need of patients as possible, are ideal for advancing early signal-finding for our programs, and remain rich in data generation and the exploration of fundamental biology questions.

Learn about our pipeline and ongoing clinical trials

Our Clinical Research Network:
clinical sites that have participated in a BVD supported clinical study as reported on clinicaltrials.gov

Seattle Cancer Care Alliance, Fred Hutch Cancer Center, University of California San Francisco, UCLA Health / Jonsson Comprehensive Cancer Center, Hoag, Avera Cancer Institute, Mayo Clinic, The University of Arizona Cancer Center, Kettering Health, Siteman Cancer Center / A National Cancer Institute Comprehensive Cancer Center, The University of Kansas Medical Center, MD Anderson Cancer Center, The START Center for Cancer Care, Metro-Minnesota Community Oncology Research Consortium (MMCORC), University of Wisconsin-Madison, Cleveland Clinic, Washington University in St. Louis, Sarah Cannon, VCU Massey Comprehensive Cancer Center, Vanderbilt University Medical Center, Rogel Cancer Center / University of Michigan Health, University of Pittsburgh Medical Center / Hillman Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital Cancer Center, Memorial Sloan Kettering Cancer Center, Mount Sinai, Columbia University Irving Medical Center, Johns Hopkins Medicine / The Sidney Kimmel Comprehensive Cancer Center, Virginia Cancer Specialists, UNC Lineberger Comprehensive Cancer Center, Duke Cancer Institute, University of Florida Health Cancer Center

Best-in-Class Early Development Network

Our focus and expertise as an organization lies in early-stage development through clinical proof-of-concept, and we have built an external network to support the execution of this work.

Activating this network appropriately as we move a program through the early stages of development enables us to apply a deep level of rigor to de-risking programs, working diligently to deliver focused data that supports whether a program or direction shows promise to address the target unmet need.

We support learning as much as we can in our clinical trials and through our far-reaching collaborations so that we can translate those insights to help current and future patients and drugs. As part of our commitment to bringing hope for life to patients, we invest in advancing the field through deep interrogation of patient biomarkers and secondary readouts in addition to advancing our own investigational medicines.

Learn more about our overall approach
to program development